Ellagic acid - Chemopreventive role in oral cancer

Journal of Cancer Science and Therapy

Volumn 4, Issue 2, 2012, Pages 23-30

  Bisen, Prakash S ^a   Bundela, Saurabh S ^a,b   Sharma, Anjana ^b  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

^b RANI DURGAVATI UNIVERSITY   (India)

Author keywords

Angiogenesis; Cancer hallmarks; Ellagic acid; Ellagitannins; Molecular targets; Oral cancer; Urolithins

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; ELLAGIC ACID; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AUTOCRINE EFFECT; CANCER CELL DESTRUCTION; CELL CYCLE REGULATION; CHEMOPROPHYLAXIS; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; METASTASIS INHIBITION; MOUTH CANCER; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84859065354     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000106     Document Type: Review

References (133)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. (2008) Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10.
2. Wake M (1993) The urban/rural divide in head and neck cancer--the effect of atmospheric pollution. Clin Otolaryngol Allied Sci 18: 298-302.
3. Massano J, Regateiro FS, Januario G, Ferreira A (2006) Oral squamous cell carcinoma: Review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 67-76.
4. Cetuximab (Erbitux®) (2009) Plus Radiation Beneficial in Head and Neck Cancer-National Cancer Institute.
5. Class Labeling Changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations.
6. August J (2010) Market watch: Emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov 9: 351.
7. Schmidt C (2011) Larger companies dominate cancer companion diagnostic approvals. Nat Biotechnol 29: 955-957.
8. Foo J, Michor F (2009) Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol 5: e1000557.
9. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 293: 876-880.
10. Vogt PK (2008) Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike. Cancer Cell 14: 107-108.
11. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
12. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, et al. (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97.
13. Chiang CS, Sawyers CL, Mcbride WH (1998) Oncogene expression and cellular radiation resistance: A modulatory role for c-myc. Mol Diagn 3: 21-27.
14. Dowsett M (2001) Overexpression of her-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8: 191-195.
15. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z (1985) Medicinal plants in therapy. Bull World Health Organ 63: 965-981.
16. Li N, Chen X, Liao J, Yang G, Wang S, et al. (2002) Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23: 1307-1313.
17. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, et al. (2008) Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 123: 1005-1014.
18. Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG (1998) Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19: 419-424.
19. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS (2008) Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 87: 401-406.
20. Yang Y, Zhou ZT, Ge JP (2006) Effect of genistein on DMBA-induced oral carcinogenesis in hamster. Carcinogenesis 27: 578-583.
21. Han C, Ding H, Casto B, Stoner GD, D'Ambrosio SM (2005) Inhibition of the growth of premalignant and malignant human oral cell lines by extracts and components of black raspberries. Nutr Cancer 51: 207-217.
22. Lu R, Dan H, Wu R, Meng W, Liu N, et al. (2011) Lycopene: features and potential significance in the oral cancer and precancerous lesions. J Oral Pathol Med 40: 361-368.
23. Thurnher D, Turhani D, Pelzmann M, Wannemacher B, Knerer B, et al. (2003) Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 25: 732-740.
24. Actis AB, López CB, Joekes S, Eynard AR (1999) N-3, n-6 and n-9 dietary fatty acids modulate the growth parameters of murine salivary gland tumors induced by dimethylbenzanthracene. Prostaglandins Leukot Essent Fatty Acids 61: 259-265.
25. Miller EG, Peacock JJ, Bourland TC, Taylor SE, Wright JM, et al. (2008) Inhibition of oral carcinogenesis by citrus flavonoids. Nutr Cancer 60: 69-74.
26. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, et al. (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315: 1501-1505.
27. Atta-Ur-Rahman, Ngounou FN, Choudhary MI, Malik S, Makhmoor T, et al. (2001) New antioxidant and antimicrobial ellagic acid derivatives from Pteleopsis hylodendron. Planta Med 67: 335-339.
28. Festa F, Aglitti T, Duranti G, Ricordy R, Perticone P, et al. (2001) Strong antioxidant activity of ellagic acid in mammalian cells in vitro revealed by the comet assay. Anticancer Res 21: 3903-3908.
29. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, et al. (2005) In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16: 360-367.
30. Narayanan BA, Geoffroy O, Willingham MC, Re GG, Nixon DW (1999) p53/ p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 136: 215-221.
31. Leonardo S, Alberto A, Raul RH, Antonio AC, Cristobal NA (2011) Ellagic acid: Biological properties and biotechnological development for production processes. Afr J Biotechnol 10: 4518-4523.
32. Boukharta M, Jalbert G, Castonguay A (1992) Biodistribution of ellagic acid and dose-related inhibition of lung tumorigenesis in A/J mice. Nutr Cancer 18: 181-189.
33. Doyle B, Griffiths LA (1980) The metabolism of ellagic acid in the rat. Xenobiotica 10: 247-256.
34. Teel RW, Babcock MS, Dixit R, Stoner GD (1986) Ellagic acid toxicity and interaction with benzo[a]pyrene and benzo[a]pyrene 7,8-dihydrodiol in human bronchial epithelial cells. Cell Biol Toxicol 2: 53-62.
35. Mandal S, Stoner GD (1990) Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis 11: 55-61.
36. Mandal S, Shivapurkar NM, Galati AJ, Stoner GD (1988) Inhibition of N-nitrosobenzylmethylamine metabolism and DNA binding in cultured rat esophagus by ellagic acid. Carcinogenesis 9: 1313-1316.
37. Siglin JC, Barch DH, Stoner GD (1995) Effects of dietary phenethyl isothiocyanate, ellagic acid, sulindac and calcium on the induction and progression of N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Carcinogenesis 16: 1101-1106.
38. Narayanan BA, Re GG (2001) IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res 21: 359-364.
39. Barch DH, Rundhaugen LM (1994) Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene. Carcinogenesis 15: 2065-2068.
40. Zhang Z, Hamilton SM, Stewart C, Strother A, Teel RW (1993) Inhibition of liver microsomal cytochrome P450 activity and metabolism of the tobacco-specific nitrosamine NNK by capsaicin and ellagic acid. Anticancer Res 13: 2341-2346.
41. Barch DH, Rundhaugen LM, Thomas PE, Kardos P, Pillay NS (1994) Dietary ellagic acid inhibits the enzymatic activity of CYP1A1 without altering hepatic concentrations of CYP1A1 or CYP1A1 mRNA. Biochem Biophys Res Commun 201: 1477-1482.
42. Narayanan BA, Narayanan NK, Stoner GD, Bullock BP (2002) Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci 70: 1821-1839.
43. Tanaka T, Iwata H, Niwa K, Mori Y, Mori H (1988) Inhibitory effect of ellagic acid on N-2-fluorenylacetamide-induced liver carcinogenesis in male ACI/N rats. Jpn J Cancer Res 79: 1297-1303.
44. Stoner GD, Kresty LA, Carlton PS, Siglin JC, Morse MA (1999) Isothiocyanates and freeze-dried strawberries as inhibitors of esophageal cancer. Toxicol Sci 52: 95-100.
45. Li TM, Chen GW, Su CC, Lin JG, Yeh CC, et al. (2005) Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res 25: 971-979.
46. Mertens-Talcott SU, Percival SS (2005) Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett 218: 141-151.
47. Hagiwara Y, Kasukabe T, Kaneko Y, Niitsu N, Okabe-Kado J (2010) Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells. Int J Hematol 92: 136-143.
48. Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G (2005) Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol 47: 449-454.
49. Tanaka T, Kojima T, Kawamori T, Wang A, Suzui M, et al. (1993) Inhibition of 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic acids. Carcinogenesis 14: 1321-1325.
50. Casto BC, Kresty LA, Kraly CL, Pearl DK, Knobloch TJ, et al. (2002) Chemoprevention of oral cancer by black raspberries. Anticancer Res 22: 4005-4015.
51. Lyophilized black raspberries in preventing oral cancer in high-risk patients previously diagnosed with stage I-IV or in situ head and neck cancer.
52. Mallery SR, Stoner GD, Larsen PE, Fields HW, Rodrigo KA, et al. (2007) Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze dried black raspberries: implications for oral cancer chemoprevention. Pharm Res 24: 728-737.
53. Shumway BS, Kresty LA, Larsen PE, Zwick JC, Lu B, et al. (2008) Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions. Clin Cancer Res 14: 2421-2430.
54. Mallery SR, Zwick JC, Pei P, Tong M, Larsen PE, et al. (2008) Topical application of a bioadhesive black raspberry gel modulates gene expression and reduces cyclooxygenase 2 protein in human premalignant oral lesions. Cancer Res 68: 4945-4957.
55. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, et al. (2011) A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 118: 156-166.
56. Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, et al. (2011) Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochem Biophys Res Commun 415: 163-167.
57. Zou J, Luo H, Zeng Q, Dong Z, Wu D, et al. (2011) Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med 9: 97.
58. Meek DW, Cox M (2011) Induction and activation of the p53 pathway: a role for the protein kinase CK2? Mol Cell Biochem 356: 133-138.
59. Barata JT (2011) The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 51: 37-49.
60. Channavajhala P, Seldin DC (2002) Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 21: 5280-5288.
61. Torrecilla I, Spragg EJ, Poulin B, McWilliams PJ, Mistry SC, et al. (2007) Phosphorylation and regulation of a G protein-coupled receptor by protein kinase CK2. J Cell Biol 177: 127-137.
62. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE (2002) Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 62: 6770-6778.
63. Faust RA, Tawfic S, Davis AT, Bubash LA, Ahmed K (2000) Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck 22: 341-346.
64. Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, et al. (2010) CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules. Clin Cancer Res 16: 2295-2307.
65. Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, et al. (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem 49: 2363-2366.
66. Sekiguchi Y, Nakaniwa T, Kinoshita T, Nakanishi I, Kitaura K, et al. (2009) Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett 19: 2920-2923.
67. Cozza G, Gianoncelli A, Bonvini P, Zorzi E, Pasquale R, et al. (2011) Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors. ChemMedChem 6: 2273-2286.
68. Wright WE, Pereira-Smith OM, Shay JW (1989) Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol 9: 3088-3092.
69. Schliephake H (2003) Prognostic relevance of molecular markers of oral cancer--a review. Int J Oral Maxillofac Surg 32: 233-245.
70. Ries JC, Hassfurther E, Steininger H, Kloss FR, Wiltfang J, et al. (2001) Correlation of telomerase activity, clinical prognosis and therapy in oral carcinogenesis. Anticancer Res 21: 1057-1063.
71. Liao J, Mitsuyasu T, Yamane K, Ohishi M (2000) Telomerase activity in oral and maxillofacial tumors. Oral Oncol 36: 347-352.
72. Freier K, Pungs S, Flechtenmacher C, Bosch FX, Lichter P, et al. (2007) Frequent high telomerase reverse transcriptase expression in primary oral squamous cell carcinoma. J Oral Pathol Med 36: 267-272.
73. Miyoshi Y, Tsukinoki K, Imaizumi T, Yamada Y, Ishizaki T, et al. (1999) Telomerase activity in oral cancer. Oral Oncol 35: 283-289.
74. Liu X, Huang H, Wang J, Wang C, Wang M, et al. (2011) Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 82: 17-23.
75. Strati A, Papoutsi Z, Lianidou E, Moutsatsou P (2009) Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem 42: 1358-1362.
76. Mishra S, Vinayak M (2011) Anti-carcinogenic action of ellagic acid mediated via modulation of oxidative stress regulated genes in Dalton lymphoma bearing mice. Leuk Lymphoma 52: 2155-2161.
77. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
78. Paterson IC, Davies M, Stone A, Huntley S, Smith E, et al. (2002) TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest. Oncogene 21: 1616-1624.
79. Mishima K, Inoue K, Hayashi Y (2002) Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol 38: 468-474.
80. Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, et al. (2008) Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 111: 4880-4891.
81. Nariai Y, Mishima K, Yoshimura Y, Sekine J (2011) FAP-1 and NF-κB expressions in oral squamous cell carcinoma as potential markers for chemoradio sensitivity and prognosis. Int J Oral Maxillofac Surg 40: 419-426.
82. Rao SK, Pavicevic Z, Du Z, Kim JG, Fan M, et al. (2010) Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 285: 32512-32521.
83. Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, et al. (2010) Activation of PI3K/Akt/IKKalpha/ NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 15: 850-863.
84. Zhang J, Peng B (2009) NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. Cell Prolif 42: 150-161.
85. Romier B, Van De Walle J, During A, Larondelle Y, Schneider YJ (2008) Modulation of signalling nuclear factor-kappaB activation pathway by polyphenols in human intestinal Caco-2 cells. Br J Nutr 100: 542-551.
86. Edderkaoui M, Odinokova I, Ohno I, Gukovsky I, Go VL, et al. (2008) Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J Gastroenterol 14: 3672-3680.
87. Mihara M, Shintani S, Nakahara Y, Kiyota A, Ueyama Y, et al. (2001) Overexpression of CDK2 is a prognostic indicator of oral cancer progression. Jpn J Cancer Res 92: 352-360.
88. Hiroi M, Mori K, Sekine K, Sakaeda Y, Shimada J, et al. (2009) Mechanisms of resistance to interferon-gamma-mediated cell growth arrest in human oral squamous carcinoma cells. J Biol Chem 284: 24869-24880.
89. Watanabe S, Watanabe R, Oton-Leite AF, Alencar Rde C, Oliveira JC, et al. (2010) Analysis of cell proliferation and pattern of invasion in oral squamous cell carcinoma. J Oral Sci 52: 417-424.
90. Xu J, Gimenez-Conti IB, Cunningham JE, Collet AM, Luna MA, et al. (1998) Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 83: 204-212.
91. Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, et al. (2009) A feed-forward loop involving protein kinase C alpha and microRNAs regulates tumor cell cycle. Cancer Res 69: 65-74.
92. Larrosa M, Tomás-Barberán FA, Espín JC (2006) The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem 17: 611-625.
93. Evan G, Littlewood T (1998) A matter of life and cell death. Science 281: 1317-1322.
94. Ishizaki Y, Cheng L, Mudge AW, Raff MC (1995) Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells. Mol Biol Cell 6: 1443-1458.
95. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285: 1028-1033.
96. Wyllie AH, Kerr JFR, Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306.
97. Han DH, Lee MJ, Kim JH (2006) Antioxidant and apoptosis-inducing activities of ellagic acid. Anticancer Res 26: 3601-3606.
98. Mantovani A, Allavena P, Sica A, Balkwill F (2002) Cancer-related inflammation. Nature 454: 436-444.
99. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.
100. Masamune A, Satoh M, Kikuta K, Suzuki N, Satoh K, et al. (2005) Ellagic acid blocks activation of pancreatic stellate cells. Biochem Pharmacol 70: 869-878.
101. Huang ST, Yang RC, Wu HT, Wang CN, Pang JH (2011) Zinc-chelation contributes to the anti-angiogenic effect of ellagic acid on inhibiting MMP-2 activity, cell migration and tube formation. PLoS One 6: e18986.
102. Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, et al. (1990) Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 50: 4771-4775.
103. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, et al. (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694.
104. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310.
105. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
106. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
107. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523-526.
108. Pérez-Sayáns M, Suárez-Peñaranda JM, Pilar GD, Barros-Angueira F, Gándara-Rey JM, et al. (2011) What real influence does the proto-oncogene c-myc have in OSCC behavior? Oral Oncol 47: 688-692.
109. Martín-Ezquerra G, Salgado R, Toll A, Gilaberte M, Baró T, et al. (2010) Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. Br J Dermatol 163: 1028-1035.
110. Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11.
111. Whitfield JR, Soucek L (2011) Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci [Epub ahead of print].
112. Sasabe E, Yang Z, Ohno S, Yamamoto T (2010) Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. Free Radic Biol Med 48: 1321-1329.
113. Rasheed MH, Beevi SS, Geetha A (2007) Enhanced lipid peroxidation and nitric oxide products with deranged antioxidant status in patients with head and neck squamous cell carcinoma. Oral Oncol 43: 333-338.
114. Manoharan S, Kolanjiappan K, Suresh K, Panjamurthy K (2005) Lipid peroxidation & antioxidants status in patients with oral squamous cell carcinoma. Indian J Med Res 122: 529-534.
115. Yang J, Lam EW, Hammad HM, Oberley TD, Oberley LW (2002) Antioxidant enzyme levels in oral squamous cell carcinoma and normal human oral epithelium. J Oral Pathol Med 31: 71-77.
116. Gokul S, Patil VS, Jailkhani R, Hallikeri K, Kattappagari KK (2010) Oxidantantioxidant status in blood and tumor tissue of oral squamous cell carcinoma patients. Oral Dis 16: 29-33.
117. Lee SE, Shin HT, Hwang HJ, Kim JH (2003) Antioxidant activity of extract from Alpinia katsumadai seed. Phytother Res 17: 1041-1047.
118. Seeram NP, Lee R, Heber D (2004) Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 348: 63-68.
119. Espín JC, González-Barrio R, Cerdá B, López-Bote C, Rey AI, et al. (2007) The lberian pig as model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 55: 10476-10485.
120. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, et al. (2006) Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 136: 2481-2485.
121. Cerdá B, Espín JC, Parra S, Martínez P, Tomás-Barberán FA (2004) The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 43: 205-220.
122. Cerdá B, Tomás-Barberán FA, Espín JC (2005) Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem 53: 227-235.
123. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, et al. (2007) Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55: 7732-7737.
124. González-Sarrías A, Giménez-Bastida JA, García-Conesa MT, Gómez-Sánchez MB, García-Talavera NV, et al. (2010) Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 54: 311-322.
125. Steinbeck C, Han Y, Kuhn S, Horlacher O, Luttmann E, et al. (2003) The Chemistry Development Kit (CDK): an open-source Java library for Chemo and Bioinformatics. J Chem Inf Comput Sci 43: 493-500.
126. Bialonska D, Kasimsetty SG, Khan SI, Ferreira D (2009) Urolithins, intestinal microbial metabolites of Pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay. J Agric Food Chem 57: 10181-10186.
127. Ishimoto H, Shibata M, Myojin Y, Ito H, Sugimoto Y, et al. (2011) In vivo antiinflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg Med Chem Lett 21: 5901-5904.
128. Adams LS, Zhang Y, Seeram NP, Heber D, Chen S (2010) Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila) 3: 108-113.
129. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
130. Mantovani A (2009) Cancer: Inflaming metastasis. Nature 457: 36-37.
131. Barch DH, Rundhaugen LM, Stoner GD, Pillay NS, Rosche WA (1996) Structure-function relationships of the dietary anticarcinogen ellagic acid. Carcinogenesis 17: 265-269.
132. Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-1822.
133. Kakran M, G Sahoo N, Bao H, Pan Y, Li L (2011) Functionalized graphene oxide as nanocarrier for loading and delivery of ellagic acid. Curr Med Chem 18: 4503-4512.